Neuropsychological and conditioned blocking performance in patients with schizophrenia: Assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy

Behavioural Pharmacology

Volumn 11, Issue 3-4, 2000, Pages 317-330

  Oades, R D ^a,b   Rao, M L ^c   Bender, S ^b   Sartory, G ^d   Muller B W ^a,b  

^a Univ Clin for Child and Adol P   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF WUPPERTAL   (Germany)

Author keywords

Antipsychotic dose; Attention; Conditioned blocking; Dopamine; Dopamine D2 receptor; Gender; Neuroleptic; Schizophrenia; Serum level

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUPENTIXOL; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; RECALL; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SELECTIVE ATTENTION; SEX DIFFERENCE; VERBAL COMMUNICATION; VISUAL MEMORY;

EID: 0033924236     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200006000-00015     Document Type: Article

References (61)

1. Aleman A, Hijman R, de Haan, EHF, Kahn RS (1999). Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358-1366.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC.
3. Amin F, Silverman JM, Siever LJ, Smith CJ, Knott PJ, Davis KL (1999). Genetic antecedents of dopamine dysfunction in schizophrenia. Biol Psychiat 45:1143-1150.
4. Andreasen NC, Olsen S (1982). Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 39:789-794.
5. Bagli M, Süverküp R, Quadflied E, Höflich G, Kasper S, Möller H-J et al. (1999). Pharmacokinetic-, pharmacodynamic-modeling of tolerance to the prolactin secreting effect of chlorprothixene of the different modes of drug administration. J Pharmacol Exp Ther 291:547-554.
6. Batra A (2000). Tabakabhängigkeit und Raucherentwöhnung bei psychiatrischen Patienten. Fortschr Neurol Psychiatrie 68:80-92.
7. Bender S, Schall U, Wolstein J, Grzella I, Zerbin D, Oades RD (1999). A topographic event-related potential follow-up study on 'prepulse inhibition' in first and second episode schizophrenia. Psychiat Res Neuroimaging 90:41-53.
8. Bender S, Müller BW, Oades RD, Sartory G (2000). Conditioned blocking and schizophrenia: a replication and study of the role of symptoms, age, onset-age of psychosis and illness-duration. Schizophr Res 43 in press.
9. Benkert O, Hippius H (1986). Psychiatrische Pharmakotherapie. 4th ed. Heidelberg: Springer-Verlag.
10. Benton AL, Hamsher K (1989). Multilingual Aphasia Examination. Iowa City, IA: AJA Associates.
11. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA (1992). Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 28:353-366.
12. Brauns H, Haun D, Steinmann S (1997). The construction of an internationally comparable classification by class. Erwerbsstatistische Besonderheiten am Beispiel von Labour Force Surveys der Bundesrepublik Deutschland, Frankreichs, Großbritanniens und Ungarns. Arbeitspapiere Arbeitsbereich 1/22, Mannheim Center for European Social Research (MZES), Mannheim.
13. Brebion G, Amador X, Smith MJ, Malaspina D, Sharif Z, Gorman J (1999). Opposite links of positive and negative symptomatology with memory errors in schizophrenia. Psychiat Res 88:15-24.
14. Di Paolo T (1994). Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5:27-42.
15. 2-dopamine receptor occupancy during treatment with flupenthixol conventional and atypical neuroleptics. Psychopharmacology 99:s28-s31.
16. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544.
17. Gilbertson MW, Yao JK, Van Kammen DP (1994). Memory and plasma HVA changes in schizophrenia: are they episode markers? Biol Psychiatry 35:203-206.
18. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992). Abolition of latent inhibition by a single 5 mg dose of D-amphetamine in man. Psychopharmacology 107:425-430.
19. Gray NS, Pilowsky LS, Gray JA, Kerwin RW (1995). Latent inhibition in drug-naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17:95-107.
20. Gray NS, Pickering AD, Gray JA, Jones SH, Abrahams SH, Hemsley DR (1997). Kamin blocking is not disrupted by amphetamine in human subjects. J Psychopharmacol 11:301-311.
21. Gurden H, Tassin J-P, Jay TM (1999). Integrity of the mesocortical dopaminergic system is necessary for complete expression of in vivo hippocampal-prefrontal cortex long-term potentiation. Neuroscience 94:1019-1027.
22. Hess EJ, Bracha S, Kleinman J. Creese I (1987). Dopamine receptor sub-type imbalance in schizophrenia. Life Sci 40:1487-1497.
23. Kamin LJ (1969). Predictability, surprise. Attention and conditioning. In: Punishment and Aversive Behavior. Church R, Campbell B (eds.). New York: Appleton-Century-Crofts, pp. 279-296.
24. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928.
25. Kane JM 1996. Drug therapy: Schizophrenia. W Engl J Med 334:34-41
26. Kay SR, Opler LA, Fizbein A (1992). The Positive and Negative Syndrome Scale (PANSS). Manual. Toronto: Multi-Health Systems.
27. 2 receptor occupancy levels. Psychiat Res 75:91-101.
28. Lansdell H (1970). Relation of extent of temporal removals to closure and visuomotor factors. Percept Motor Skills 31:491-498.
29. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72.
30. Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BPR, van Royen EA (1999). Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiat Res Neuroimaging 92:33-44.
31. Li B-M, Mao Z-M, Wang M, Mei Z-T (1999). Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 21:601-610.
32. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
33. Mooney CM, Ferguson GA (1951). A new closure test. Can J Psychol 5:129-133.
34. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449.
35. 2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry 55:283-284.
36. 2 dopamine receptor availability after discontinuation of haloperidol decanoate. Arch Gen Psychiatry 54:953-958.
37. 2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-875.
38. Oades RD, Rivet J-M, Taghzouti K, Kharouby M, Simon H, Le Moal M (1987). Catecholamines and conditioned blocking: effects of ventral tegmental, septal and frontal 6-hydroxydopamine lesions in rats. Brain Res 406:136-146.
39. Oades RD, Röpcke B, Eggers C (1994). Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis. J Neural Transm 96:143-159.
40. Oades RD, Röpcke B, Schepker R (1996a). A test of conditioned blocking and its development in childhood and adolescence: relationship to personality and monoamine metabolism. Dev Neuropsychology 12:207-230.
41. Oades RD, Zimmermann B, Eggers C (1996b). Conditioned blocking in patients with paranoid, non-paranoid psychosis or obsessive compulsive disorder: associations with symptoms, personality and monoamine metabolism. J Psychiatr Res 30:369-390.
42. Oades RD, Heeper C, Czwenk A, Eisenbeis I, Fierro L, Dolberg A, Müller B (2000). What neuropsycological signs are associated with the presence or absence of conditioned blocking in schizophrenia? Schizophr Res 41:291.
43. Oldfield RC (1971). The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia 9:97-113.
44. 2 dopamine receptor occupancy in clozapine-treated patients. Am J Psychiatry 153:1571-1578.
45. 2 receptor occupancy in patients treated with olanzapine. Psychiat Res 90:81-90.
46. Rao ML (1986). Modification of the radioreceptor assay technique for estimation of serum neuroleptic drug levels leads to improved precision and sensitivity. Psychopharmacology 90:548-553.
47. Raven JC (1976). Raren-Matrizen-Test: Advanced Progressive Matrices. German language manual. Kratzmeier H, Horn R (eds.). Stuttgart: Beltz-Verlag.
48. Reitan RM (1958). The validity of the Trail Making Test as an indicator of organic brain damage. Percept Motor Skills 8:271-276.
49. 2 occupancy: a positron emission tomographic study. J Clin Psychopharmacology 18:82-83.
50. Rey M-J, Schulz P, Costa C, Dick P, Tissot R (1989). Guidelines for the dosage of neuroleptics. 1: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacology 4:95-104.
51. Schulz P, Rey M-J, Dick P, Tissot R (1989). Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long-acting injectable neuroleptics. Int Clin Psychopharmacology 4:105-114.
52. Seeman P (1997). Neurobiology of dopamine receptors, neuroleptics and schizophrenia. Biol Psychiatry 42:198-199s
53. Seeman P, Kapur S (1997). Clozapine occupies high levels of dopamine D, receptors. Life Sci 60:207-216.
54. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand Suppl 212:1-19.
55. Spohn HE, Strauss ME (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98:367-380.
56. Straube ER, Oades RD (1992). Schizophrenia: Empirical Research and Findings. San Diego: Academic Press.
57. 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141:175-181.
58. Wechsler D (1981). Wechsler Adult Intelligence Scale-revised (WAIS-R). New York: The Psychological Corporation.
59. Wechsler D (1987). The Wechsler Memory Scale-Rerised. The Psychological Corporation. San Antonio, TX: Harcourt Brace Jovanovich.
60. 2-Dopaminrezeptor-Blockade für die antipsychotische Wirkung von Neuroleptika. Eine PET-Studie an schizophrenen Patienten. In: Thioxanthene in der Neuroleptika-Behandlung. Müller-Oerlinghausen B, Möller HJ, Rüther E (eds.). New York: Springer-Verlag, pp. 13-24.
61. Williams LM, Gordon E (2000). 'Masked' span of apprehension in schizophrenic subgroups. Cog Neuropsychiatry 5:37-52.